Core Viewpoint - BioPorto A/S has submitted its FDA pre-submission package for the U.S. adult urine NGAL program, marking a significant regulatory milestone following positive preliminary analysis of the NGAL Cut-off Study [1][2][3]. Group 1: Regulatory Progress - The preliminary analysis of the NGAL Cut-off Study supports the primary endpoint, laying the groundwork for the next phase of the regulatory strategy [2]. - The submission of the FDA pre-submission package aims to obtain feedback on the proposed clinical study design for the upcoming Validation Study, which is crucial for achieving U.S. regulatory 510(k) clearance [2][3]. Group 2: Company Insights - CEO Carsten Buhl emphasized that the FDA pre-submission is a critical milestone for BioPorto, and the positive results from the cut-off study support the advancement of the U.S. adult urine NGAL program [3]. - BioPorto's financial guidance remains unchanged as of the latest announcement on February 5, 2026 [3]. Group 3: Product Focus - BioPorto specializes in in vitro diagnostics, particularly focusing on actionable biomarkers to aid clinicians in patient management [7]. - The flagship products are based on the NGAL biomarker, which assists in the risk assessment and diagnosis of Acute Kidney Injury (AKI), a condition that can lead to severe health consequences if not addressed promptly [8].

Group 1 - The KDIGO 2026 Clinical Practice Guideline Draft for Acute Kidney Injury (AKI) and Acute Kidney Disease (AKD) has been published, marking the first major update since 2012, focusing on early detection and risk prediction [1][2] - The new guidelines emphasize the continuum of AKI and AKD, highlighting the need for precise diagnosis using functional measures and structural biomarkers, along with improved clinical decision support tools [2][3] - KDIGO's updated framework reflects a global shift towards earlier identification and intervention in acute kidney disorders, which is seen as a significant advancement for clinicians and patients [3] Group 2 - BioPorto A/S specializes in in vitro diagnostics, focusing on actionable biomarkers to enhance patient management and improve clinical outcomes [4][5] - The company's flagship products utilize the NGAL biomarker to aid in the risk assessment and diagnosis of AKI, allowing for faster identification of at-risk patients compared to standard care [5] - BioPorto's NGAL tests are marketed under applicable registrations, including CE mark, in various countries worldwide [5]

Core Insights - BioPorto A/S announced its annual financial results for 2025, confirming preliminary figures released earlier in February 2026 [1][2]. Financial Performance - Total revenue for FY 2025 reached DKK 40.3 million, reflecting an 11% increase from FY 2024 and a 13% increase at constant exchange rates (CER), aligning with the guidance of DKK 40-45 million [3][4]. - Total NGAL revenue increased to DKK 28.2 million, marking a 22% growth year-over-year and a 25% increase at CER [3][4]. - US NGAL revenue from Research Use Only (RUO) rose by 25% to DKK 18.4 million, with a 29% increase at CER [3][4]. - Adjusted EBITDA loss for 2025 was DKK 76.5 million, an 8% increase compared to 2024, within the guidance range of DKK 75-80 million [3][4]. - Cash and cash equivalents decreased to DKK 54.9 million from DKK 59.7 million in 2024, representing an 8% decline [3][4]. Strategic Developments - The company successfully secured commercial availability of ProNephro AKI (NGAL) for the US market through its distributor [5]. - A three-year "Forward" Strategic Plan was established in November 2025, focusing on market adoption and expansion towards 2028 [5]. - BioPorto executed a Financing Strategy with private placements totaling DKK 76.5 million in April and November 2025 [5]. - Patient enrollment for the ProNephro AKI (NGAL) study for adult use was completed by the end of October 2025, with plans to submit a pre-submission meeting request to the FDA in March 2026 [5]. Future Guidance - Guidance for FY 2026 remains unchanged, with total revenue expected to be between DKK 48-58 million, representing a 20-45% increase [6]. - Total NGAL revenue for FY 2026 is projected to be between DKK 33-42 million, indicating a 20-50% growth [6]. - Adjusted EBITDA loss for FY 2026 is anticipated to be between DKK 50-60 million, a decrease of 22-35% [6]. - The company aims for revenue between DKK 150-200 million by FY 2028, with an adjusted EBITDA margin of at least 15% [6].

Core Viewpoint - BioPorto A/S has announced positive preliminary results from its U.S. adult NGAL Cutoff Study, which evaluates the performance of NGAL in assessing the risk of acute kidney injury (AKI) and plans to submit an FDA Pre-submission package by the end of Q1 2026 [1][2][3] Group 1: Study Results and Regulatory Strategy - The patient enrollment for the adult study was completed in October 2025, with database lock finalized in March 2026, showing positive results that support the primary endpoint [2] - The findings are consistent with previous studies conducted in the pediatric segment, which led to FDA clearance for the pediatric indication at the end of 2023, providing a strong foundation for BioPorto's regulatory strategy [2] - The planned Pre-submission will seek FDA feedback on the regulatory pathway and study protocols for the subsequent Validation Study [3] Group 2: Company Leadership and Milestones - BioPorto's Senior Medical Director expressed confidence in the results, indicating strong support for NGAL as a biomarker for identifying AKI risk in critically ill adults [3] - The CEO highlighted the analysis as a major milestone, emphasizing the importance of the Pre-submission step for designing the optimal Validation Study [4] - The announcement does not alter BioPorto's financial guidance as published on February 5, 2026 [4] Group 3: Company Overview and Product Focus - BioPorto is focused on in vitro diagnostics, aiming to improve patient management through actionable biomarkers, particularly in areas with significant unmet medical needs [8] - The company's flagship products utilize the NGAL biomarker to aid in the risk assessment and diagnosis of AKI, enabling earlier intervention and tailored patient management strategies [9] - BioPorto operates facilities in Copenhagen, Denmark, and Boston, MA, USA, and is listed on the Nasdaq Copenhagen stock exchange [10]

Core Viewpoint - BioPorto A/S has appointed Klaus Juhl Wulff as the new Executive Vice President and Chief Financial Officer, effective May 1, 2026, highlighting the company's commitment to strengthening its management team for anticipated growth [1][2][3]. Company Overview - BioPorto is an in vitro diagnostics company focused on improving patient management through actionable biomarkers, aiming to address significant unmet medical needs [4]. - The company specializes in developing products that enhance clinical and economic outcomes for patients and healthcare providers [4]. Key Products - BioPorto's flagship products utilize the NGAL biomarker to assist in the risk assessment and diagnosis of Acute Kidney Injury (AKI), which can lead to severe health consequences if not treated promptly [5]. - The NGAL tests allow for quicker identification of patients at risk of AKI compared to standard care measurements, facilitating earlier interventions [5]. Leadership Appointment - Klaus Juhl Wulff brings over 20 years of experience in finance, operations, M&A, and capital markets, previously serving as CFO at AquaPorin A/S [2]. - The CEO of BioPorto, Carsten Buhl, expressed confidence in Wulff's ability to contribute strategically, particularly in supply chain management to support the company's growth trajectory [3].

Core Viewpoint - BioPorto A/S has announced preliminary unaudited financial figures for 2025, providing guidance for 2026 and an update on its business strategy, indicating strong growth in its NGAL product line and a focus on expanding market adoption in the U.S. [1][4][11] Financial Performance - In Q4 2025, total revenue reached DKK 11.6 million, a 47% increase compared to Q4 2024, with a 52% increase at constant exchange rates [3][8] - For the fiscal year 2025, total revenue was DKK 40.3 million, up 11% from DKK 36.2 million in 2024, with a 13% increase at constant exchange rates [3][8] - Total NGAL revenue for FY 2025 was DKK 28.2 million, reflecting a 22% growth year-over-year [3][8] - The adjusted EBITDA loss for FY 2025 is estimated at approximately DKK 77 million, aligning with previous guidance [3][8] 2026 Financial Guidance - For 2026, BioPorto targets total revenue of DKK 48-58 million, representing a growth of 20-45% [6][9] - Total NGAL revenue is expected to grow by 20-50%, reaching DKK 33-42 million [6][9] - The adjusted EBITDA loss for 2026 is projected to be between DKK 50-60 million, indicating a decrease in loss of 22-35% compared to 2025 [9] Business Strategy and Market Adoption - The company is pursuing over 60 active hospitals in the U.S. by the end of 2026 as part of its "Forward" strategy [6][11] - By the end of 2025, there were 44 active hospitals using NGAL for Research Use Only (RUO), an increase of 8 from the previous year [14] - BioPorto is preparing for a clinical validation study for adults, with a pre-submission package to the FDA expected by the end of Q1 2026 [14] Future Aspirations - The company aims for revenue between DKK 150-200 million by FY 2028, with an adjusted EBITDA margin of at least 15% [9] - Cash flow is expected to turn positive in the second half of 2027, with current cash reserves projected to cover expenses through 2026 [9]

Core Viewpoint - BioPorto A/S has announced preliminary unaudited financial figures for 2025, providing guidance for 2026 and an update on its business strategy, indicating strong growth in revenue driven by its NGAL product line, particularly in the U.S. market [1][4][6]. Financial Performance - In Q4 2025, total revenue reached DKK 11.6 million, a 47% increase compared to Q4 2024, with a 52% increase at constant exchange rates [3][7]. - For the fiscal year 2025, total revenue was DKK 40.3 million, an 11% increase from DKK 36.2 million in 2024, with a 13% growth at constant exchange rates [3][7]. - Total NGAL revenue for FY 2025 was DKK 28.2 million, reflecting a 22% increase from the previous year [3][7]. - The adjusted EBITDA loss for FY 2025 is estimated at DKK 77 million, aligning with the guidance of a loss between DKK 75-80 million [3][7]. 2026 Financial Guidance - For 2026, BioPorto expects total revenue to be between DKK 48-58 million, representing a growth of 20-45% [6][8]. - Total NGAL revenue is projected to grow by 20-50%, reaching DKK 33-42 million [6][8]. - The adjusted EBITDA loss for 2026 is anticipated to be between DKK 50-60 million, indicating a decrease in loss of 22-35% compared to 2025 [8]. Business Strategy and Market Adoption - The company is focused on executing its "Forward" strategy, aiming to increase market adoption of its NGAL test, with a target of over 60 active hospitals in the U.S. by the end of 2026 [6][10][12]. - By the end of 2025, BioPorto had established 44 active hospitals for NGAL RUO, an increase of 8 from the previous year [12]. - The company is preparing for a clinical validation study for adults, with a pre-submission package to the FDA expected by the end of Q1 2026 [12]. Future Aspirations - BioPorto aims for revenue between DKK 150-200 million by FY 2028, with an adjusted EBITDA margin of at least 15% [8]. - The company expects to achieve positive cash flow in the second half of 2027, with current cash reserves projected to cover expenses through 2026 [8].

Group 1 - The Nipah virus outbreak in West Bengal, India has confirmed 5 cases with nearly 100 people under observation, prompting neighboring countries like Thailand and Nepal to enhance health screening for travelers from India [1] - The World Health Organization (WHO) classifies the Nipah virus as a high-priority regional threat due to its high mortality rate of 40%-70% and the absence of approved vaccines or treatments [4][11] - The research team from Wuhan Institute of Virology has published findings indicating that the oral nucleoside drug VV116 shows significant antiviral activity against the Nipah virus, providing new hope for treatment [2][8] Group 2 - VV116, developed by Wangshan Wangshui and Junshi Biosciences, has shown potential against various RNA viruses, including the Nipah virus, and has been approved for COVID-19 treatment in China and Uzbekistan [7][8] - Following the announcement of VV116's efficacy against the Nipah virus, shares of Wangshan Wangshui surged by 10.9%, reaching a new high since its listing in November 2025 [4][5] - The market response to the Nipah virus outbreak has led to significant stock price increases for several companies involved in diagnostic testing, with companies like Kaipu Biological and Da'an Gene reporting substantial gains [12][13]

Core Viewpoint - BioPorto A/S announced the resignation of CFO Niels Høy Nielsen, who will continue in his role until March 2026, as he transitions to a new position at another company [1][2]. Company Overview - BioPorto is an in vitro diagnostics company focused on improving patient management through actionable biomarkers, particularly in areas with significant unmet medical needs [4]. - The company utilizes its expertise in antibodies and assay development to create innovative products aimed at enhancing clinical and economic outcomes for patients and healthcare providers [4]. Key Products - BioPorto's flagship products are based on the NGAL biomarker, which aids in the risk assessment and diagnosis of Acute Kidney Injury (AKI) [5]. - The NGAL tests allow for quicker identification of patients at risk of AKI compared to standard care measurements, facilitating earlier intervention and tailored management strategies [5]. Company Operations - BioPorto operates facilities in Copenhagen, Denmark, and Boston, MA, USA, and is listed on the Nasdaq Copenhagen stock exchange [6].

Core Points - BioPorto A/S has completed a private placement of 40,438,426 new shares, raising approximately DKK 43 million in new capital [1][2] - The new shares represent 8.89% of BioPorto's registered share capital prior to the increase [2] - The nominal share capital of BioPorto now amounts to DKK 495,108,887, consisting of 495,108,887 shares [4] Company Overview - BioPorto is an in vitro diagnostics company focused on improving patient outcomes through actionable kidney biomarkers, particularly for Acute Kidney Injury (AKI) [5] - The company's flagship products utilize the NGAL biomarker to aid in the risk assessment and management of AKI, enabling earlier intervention [5] - BioPorto's tests are marketed under various registrations, including CE mark in several countries and FDA clearance for ProNephro AKI™ in the US [5] Trading and Listing - The new shares will be admitted to trading and officially listed on Nasdaq Copenhagen A/S under the company's permanent ISIN code [3] - The new shares carry the same rights as existing shares, including the right to receive dividends from the time the capital increase is registered [3] Capital Structure - Following the capital increase, BioPorto's Articles of Association have been updated to reflect the new share capital structure [4] - The company emphasizes its commitment to transparency and provides access to its announcements and relevant information through its investor relations platform [4]